Latest Commercialisation News

Rhythm Biosciences has completed critical validation of its ColoSTAT colorectal cancer assay and submitted it for ISO15189 accreditation, paving the way for commercialisation. The test demonstrated strong clinical performance, highlighting its potential as a non-invasive diagnostic tool.

Centrepoint Alliance has reported a robust FY25 with 13% revenue growth and a 30% increase in profit before tax, driven by organic adviser expansion, strategic acquisitions, and pioneering technology investments including AI and cybersecurity.

Centrepoint Alliance has reported a robust FY25 financial performance, surpassing earnings guidance with a 16% rise in EBITDA and a 30% jump in pre-tax profits. The company also declared a 1.75 cent final dividend and advanced its technology and advisory services.

Bio-Gene Technology Limited reported a net loss of AUD 2.58 million for FY2025 while making significant strides in developing its bio-insecticides Flavocide and Qcide, securing US Department of Defense grants and expanding global partnerships.

Nanosonics delivered a robust FY25 with 17% revenue growth and a 72% jump in profit before tax, propelled by next-gen trophon devices and advancing CORIS commercialisation.

Premier1 Lithium has announced its first inferred mineral resource at the Wadgingarra gold project, marking a significant step towards commercial gold production with promising expansion potential.

Sparc Technologies reveals up to 60% corrosion reduction in graphene-enhanced water-based epoxy coatings, reinforcing its leadership in sustainable protective coatings innovation.

Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.

Alligator Energy has secured final regulatory approval to begin its in-situ Field Recovery Trial at the Samphire Uranium Project, advancing the development of its recently upgraded Blackbush Deposit resource.

LTR Pharma’s SPONTAN nasal spray has achieved unanimous patient satisfaction in treating erectile dysfunction after prostate surgery, signaling a promising shift in therapy preferences.

Carnegie Clean Energy reported a $2.33 million net loss for FY2025 but made significant strides in commercialising its wave energy technologies, supported by new loans and a US subsidiary launch.

Nanoveu, via its subsidiary EMASS, has expanded its U.S. sales network with key manufacturer representatives to fast-track adoption of its ECS-DoT ultra-low power Edge AI chip across critical OEM hubs.